diprovocim

synthetic small molecule agonist of TLR2 and TLR1

Also Known As:

(3R,4R)-1-(4-((3R,4R)-3,4-bis(((1R,2S)-2-phenylcyclopropyl)carbamoyl)pyrrolidine-1-carbonyl)benzoyl)-3-N,4-N-bis((1R,2S)-2-phenylcyclopropyl)pyrrolidine-3,4-dicarboxamide

Networked: 4 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Alicyclic Hydrocarbons: 1
      - Cycloparaffins: 6
        Cyclopropanes: 9
        diprovocim: 4
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrrolidines: 115
    - diprovocim: 4

Experts

1.	Beutler, Bruce: 2 articles (01/2019 - 11/2018)
2.	Boger, Dale L: 2 articles (01/2019 - 11/2018)
3.	Jones, Brian T: 2 articles (01/2019 - 11/2018)
4.	Mifune, Yuto: 2 articles (01/2019 - 11/2018)
5.	Moresco, Eva Marie Y: 2 articles (01/2019 - 11/2018)
6.	Morin, Matthew D: 2 articles (01/2019 - 11/2018)
7.	Su, Lijing: 2 articles (01/2019 - 11/2018)
8.	Wang, Ying: 2 articles (01/2019 - 11/2018)
9.	Zhang, Hong: 2 articles (01/2019 - 11/2018)
10.	Wang, Junmei: 1 article (01/2019)

Related Diseases

1.	Neoplasms (Cancer) 11/01/2018 - "Diprovocim induced greater frequencies of tumor-infiltrating leukocytes than alum, of which CD8 T cells were necessary for the antitumor effect of immunization plus anti-PD-L1 treatment." 11/01/2018 - "In mice, Diprovocim-adjuvanted ovalbumin immunization promoted antigen-specific humoral and CTL responses and synergized with anti-PD-L1 treatment to inhibit tumor growth, generating long-term antitumor memory, curing or prolonging survival of mice engrafted with the murine melanoma B16-OVA. " 01/01/2023 - "Therefore, using subunit proteins to support Diprovocim by π-π stacking provides a new approach for the preparation and application of novel vaccines for tumor therapy and prevention of infectious diseases. "
2.	Melanoma (Melanoma, Malignant) 01/01/2019 - "Diprovocim is a recently discovered exceptionally potent, synthetic small molecule agonist of TLR2/TLR1 and has shown significant adjuvant activity in anticancer vaccination against murine melanoma. " 11/01/2018 - "Adjuvant effect of the novel TLR1/TLR2 agonist Diprovocim synergizes with anti-PD-L1 to eliminate melanoma in mice." 11/01/2018 - "In mice, Diprovocim-adjuvanted ovalbumin immunization promoted antigen-specific humoral and CTL responses and synergized with anti-PD-L1 treatment to inhibit tumor growth, generating long-term antitumor memory, curing or prolonging survival of mice engrafted with the murine melanoma B16-OVA. "
3.	Inflammation (Inflammations) 07/03/2023 - "The NF-E2 related factor-2 (Nrf2) inhibitor ML385 and nuclear factor-κB (NF-κB) agonist diprovocim were used to confirm whether IGF1 regulates inflammation and ER stress through Nrf2/NF-κB signaling. "
4.	Communicable Diseases (Infectious Diseases) 01/01/2023 - "Therefore, using subunit proteins to support Diprovocim by π-π stacking provides a new approach for the preparation and application of novel vaccines for tumor therapy and prevention of infectious diseases. "

Related Drugs and Biologics

1.	Vaccines
2.	Proteins (Proteins, Gene)
3.	Ovalbumin
4.	Antigens
5.	aluminum sulfate (alum)

Related Therapies and Procedures

1.	Therapeutics